PF-07799544 for Advanced Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Recruiting
Phase 1
Interventional Study
Melanoma
Glioma
Thyroid Cancer
Non-Small Cell Lung Cancer
Malignant Neoplasms
Brain Neoplasms
Advanced or Metastatic Solid Tumors
HGG
LGG
Low Grade Glioma
High Grade Glioma
Differentiated Thyroid Cancer
NSCLC (Non-small Cell Lung Cancer)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 16 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 124 (estimated)
- Sponsor
- Pfizer · Industry
Who this trial is looking for
This trial is looking for adults with advanced solid tumors that have a specific gene mutation. Participants will take two study medications as tablets at home twice a day until their cancer stops responding or they have too many side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with an advanced solid tumor.
- I have a measurable disease.
- I have a BRAF V600 mutation.
- I have received prior treatment for my cancer.
You may not be able to join if
- I have had another active cancer in the past 3 years.
- I have leptomeningeal disease.
- I have had retinal vein occlusion or retinal degenerative disease.
- I have a neuromuscular disorder with high creatine kinase levels.
- I have an active gastrointestinal disease.
- I have a history of interstitial lung disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).
Phase 1a is no longer ope…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Phase 1b Inclusion Criteria:
* Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
* Measurable disease by RECIST version 1.1
* Evidence of a BRAF V600 mutation
* Prior therapy per tumor cohort
* Adequate organ function per protocol
Phase 1b Exclusion Criteria:
* Other acti…
Contacts